Which is the most appropriate nursing action when the nurse notes an asymmetric, irregular, darkly pigmented mole on the back of a patient who is receiving levodopa and rasagiline for Parkinson disease?

A. Simply continuing to assess the patient is insufficient. An asymmetric, irregular, darkly pigmented mole may indicate malignant melanoma, which requires prompt evaluation and documentation. Waiting without notifying the provider could delay diagnosis and treatment. B. Stopping levodopa is not the immediate action. While levodopa has been associated with pigmentation changes, the priority is to assess for possible malignancy rather than discontinuing the medication without a provider’s evaluation. C. Advising the patient to consult a dermatologist is helpful, but the nurse’s responsibility includes notifying the prescriber to ensure timely medical evaluation and intervention. Leaving it solely to the patient could delay care. D. The nurse should notify the prescriber immediately, describing the mole’s characteristics—asymmetry, irregular borders, dark pigmentation, or rapid changes—so that the provider can order appropriate diagnostic tests, such as dermatologic evaluation or biopsy. Early recognition of melanoma is critical for prognosis and treatment outcomes.